Næste

Automatisk afspilning

Defining Progression in Metastatic Kidney Cancer

3 Visninger • 06/26/23
Del
Indlejre
administrator
administrator
Abonnenter
0

Panelists Robert A. Figlin, MD; Michael R. Harrison, MD; David I. Quinn, MBBS, PhD; and Eric Jonasch, MD, discuss defining clinical progression and optimizing use of VEGF TKI therapy to achieve the highest dose intensity before switching in patients with metastatic kidney cancer.

Vis mere
0 Kommentarer sort Sorter efter
Facebook kommentarer

Næste

Automatisk afspilning